




RealRate

PHARMACEUTICAL 2021

Dianthus Therapeutics Inc DE
Rank 100 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Dianthus Therapeutics Inc DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dianthus Therapeutics Inc DE compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 117% points. The greatest weakness of Dianthus Therapeutics Inc DE is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 346%, being 90% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	151,527
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,430
Liabilities, Non-Current	0
Other Assets	1,780
Other Compr. Net Income	-31
Other Expenses	0
Other Liabilities	6,283
Other Net Income	0
Other Revenues	3,766
Property and Equipment	8,312
Research and Development	50,615
Selling, General and Administrative Expense	28,087

Output Variable	Value in 1000 USD
Assets	161,619
Liabilities	17,713
Expenses	78,702
Revenues	3,766
Stockholders Equity	143,906
Net Income	-74,936
Comprehensive Net Income	-74,952
BaseVar	130,916
ECR before LimitedLiability	266%
Economic Capital Ratio	346%